Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care)

INTRODUCTION: Cabozantinib monotherapy is an option for treatment of advanced renal cell carcinoma (RCC). However, cabozantinib dose modification and discontinuation due to symptomatic adverse events (AEs) remains a challenge. The use of patient-reported outcomes (PROs) may help manage symptomatic A...

Descripción completa

Detalles Bibliográficos
Autores principales: Osawa, Takahiro, Fujii, Yasuhisa, Kimura, Go, Kitamura, Hiroshi, Nagashima, Yoji, Iizumi, Sakura, Osaka, Tsuyoshi, Tsubouchi, Ryoichi, Shinohara, Nobuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373669/
https://www.ncbi.nlm.nih.gov/pubmed/37495393
http://dx.doi.org/10.1136/bmjopen-2022-070275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373669/
https://www.ncbi.nlm.nih.gov/pubmed/37495393
http://dx.doi.org/10.1136/bmjopen-2022-070275

Ejemplares similares